Afatinib Crystalline Salts Polymorphism Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Afatinib formulations face challenges with polymorphism, stability, and bioavailability, which affect their therapeutic efficacy and handling characteristics, necessitating the development of new crystalline forms with improved properties.
Innovation Solution
The development of novel crystalline mono- and difumarate salts of Afatinib, including specific polymorphic forms and pharmaceutical compositions, which enhance chemical purity, solubility, stability, and bioavailability, and are characterized by XRPD patterns and other solid-state analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional Afatinib formulations are used, then the basic therapeutic activity is maintained, but polymorphism and stability issues arise affecting therapeutic efficacy and handling characteristics
Solution Approach 1:
The patent changes the chemical form of Afatinib from free base to crystalline mono- and difumarate salts, which fundamentally alters the solid-state properties and resolves polymorphism issues while maintaining therapeutic efficacy
Solution Approach 2:
The invention creates composite crystalline structures by forming salt complexes between Afatinib and fumaric acid, resulting in new crystalline forms with improved stability and defined polymorphic characteristics
2Reliability
If new crystalline forms are developed to improve stability and bioavailability, then therapeutic efficacy is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent modifies the chemical parameters of Afatinib by forming crystalline salts with fumaric acid, which simplifies manufacturing by providing defined polymorphic forms with consistent properties, rather than dealing with complex free base formulations
Solution Approach 2:
The invention creates replicated crystalline structures through salt formation, where the fumarate salt crystals serve as reproducible templates that can be manufactured consistently, improving manufacturing reliability
3Ease of manufacture
If conventional formulations are used, then production processes are simple, but processing properties such as hygroscopicity and dissolution profiles are inferior
Solution Approach 1:
The patent changes the physical-chemical parameters of Afatinib by forming crystalline fumarate salts, which fundamentally improves processing properties by reducing hygroscopicity and enhancing dissolution profiles through defined crystal structures
Solution Approach 2:
The invention utilizes phase transition principles in crystal formation, where the transformation to crystalline salt forms provides stable solid-state structures with superior processing characteristics compared to amorphous or hydrate forms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystalline forms exhibit improved bioavailability, stability, and processing properties, such as reduced hygroscopicity and enhanced dissolution profiles, leading to improved therapeutic efficacy and manufacturing consistency.
Implementation Method 1
One or more of these techniques may be used to distinguish different polymorphic forms of a compound... X-ray powder diffraction (XRPD or powder XRD) pattern
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Afatinib salts and crystalline forms thereof are described in the present application and processes for their preparation. Crystalline forms of Afatinib are also described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such Afatinib salts and crystalline forms thereof or crystalline forms of Afatinib, methods of their preparation and the use thereof in the treatment of a patient in need thereof.